Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

1 in 7 Caribbean Adults With Breast or Ovarian Cancers Have Actionable Pathogenic Variants

March 10th 2021

One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.

FDA Grants Priority Review to Pafolacianine Sodium Injection in Ovarian Cancer

March 3rd 2021

The FDA has granted priority review to the new drug application for the novel compound pafolacianine sodium injection for use in the identification of ovarian cancer during surgery.

Dr. Krivak on the Importance of Germline Genetic Testing in Ovarian Cancer

March 1st 2021

Thomas C. Krivak, MD, discusses the importance of germline genetic testing in ovarian cancer.

Dr. Wenham on Rationale for Novel Immunotherapy Combos in Ovarian Cancer

February 24th 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses novel immunotherapy combinations for the treatment of patients with ovarian cancer.

Phase 3 OVAL Trial of VB-111 in Platinum-Resistant Ovarian Cancer Gets Green Light to Continue

February 24th 2021

February 24, 2021 - An independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.

Novel CDH6-Targeted ADC DS-6000 Enters the Pipeline in RCC and Ovarian Cancer

February 23rd 2021

February 23, 2021 - The first patient in a first-in-human phase 1 study has been dosed with DS-6000, a novel CDH6-directed antibody-drug conjugate.

FDA Grants Fast Track Status to Immunotherapy GEN-1 in Advanced Ovarian Cancer

February 22nd 2021

February 22, 2021 - The FDA has granted a fast track designation to the DNA-mediated interleukin-12 immunotherapy GEN-1 for use in the treatment of patients with advanced ovarian cancer.

Germline Genetic Testing Gap Persists in Ovarian Cancer, More Delimited Panel Composition Needed to Improve Utility

February 16th 2021

February 16, 2021 - Only 34.3% of 14,689 patients with ovarian cancer received germline genetic testing between 2013 and 2019, revealing persistent underuse of testing among this population.

Dr. Chern on Opportunities for PARP Combinations in Recurrent Ovarian Cancer

February 16th 2021

Jing-Yi Chern, MD, ScM, discusses efforts being made to combine PARP inhibitors with chemotherapy and immunotherapy in patients with recurrent ovarian cancer.

Dr. Brown on Future Directions for Surgery in Ovarian Cancer

February 5th 2021

Jubilee Brown, MD, discusses future directions for surgery in ovarian cancer.

Dr. Cohen on the Efficacy of PARP Inhibitors in Ovarian Cancer

February 5th 2021

Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in patients with ovarian cancer.

Dr. Markman on the Need for Comparative Trials With PARP Inhibitors in Ovarian Cancer

February 3rd 2021

Maurie Markman, MD, discusses the need for comparative clinical trials with PARP inhibitors in ovarian cancer.

PFS Deserves More Than Surrogate Status as a Clinical Trial End Point

January 20th 2021

Although recent benefits do not pertain to all cancers and “cure” remains a relatively uncommon event, oncologists have an increasing number of molecularly targeted and immunotherapeutic strategies to employ based on objectively meaningful clinical trial outcomes.

Dr. Lees on the Utility of Genetic Testing in Ovarian Cancer

January 14th 2021

Brittany F. Lees, MD, discusses the utility of genetic and genomic testing in ovarian cancer.

Dr. Konecny on the Survival Benefit Achieved With Maintenance PARP Inhibitors in Ovarian Cancer

January 14th 2021

Gottfried E. Konecny, MD, discusses the impact of maintenance PARP inhibitors on survival in patients with ovarian cancer.

Dr. Zakhour on Clinical Trials Examining Frontline Maintenance PARP Inhibitors in Ovarian Cancer

January 14th 2021

Mae Zakhour, MD, discusses clinical trials that evaluated frontline maintenance PARP inhibitors in patients with ovarian cancer.

Dr. Naumann on the TOPACIO Trial With Pembrolizumab/Niraparib in Ovarian Cancer

January 12th 2021

R. Wendel Naumann, MD, discusses the significance of the phase 1/2 TOPACIO trial in ovarian cancer.

Dr. Puechl on Choosing Between PARP Inhibitors in Ovarian Cancer

January 11th 2021

Allison M. Puechl, MD, discusses choosing between PARP inhibitors in ovarian cancer.

Questions Remain Regarding PARP Inhibition in Recurrent Platinum-Sensitive Ovarian Cancer

January 11th 2021

Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in ovarian cancer, remaining questions regarding repeat inhibition and treatment duration, and the potential for combinations.

Dr. Crane on the Benefit of Maintenance PARP Inhibitors in Ovarian Cancer

January 8th 2021

Erin K. Crane, MD, MPH, discusses the benefit of maintenance PARP inhibitors in ovarian cancer.